Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3  Years with CNS Malignancies

ConclusionsSerum peak concentrations of bevacizumab in children under the age of 3  years with CNS malignancies are in a similar magnitude to that found in older children and adults. Thus, a dosing schedule of bevacizumab 10 mg/kg every 2 weeks can be considered sufficient and safe, even in very young children. We further show that very young children with CNS malignancies show a markedly reduced plasma clearance, possibly related to lower body weight or differences in clearance mechanisms of antibodies.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research